EMElizaveta G. Medvedeva

Elizaveta G. Medvedeva

*This is an algorithmically generated author record based on publicly available information.

Elizaveta G. Medvedeva has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical role of rudimentary structures of the right atrium

    by V.E. Milyukov, V.A. Bryukhanov, E.G. Medvedeva

    This review presents current literature data on anatomical structure and functional significance of rudimentary structures of the right atrium, as well as clinical significance of these structures including potential role for clotting.

  • Open Access

    Analysis of arterial stiffness parameters in breast cancer patients undergoing combination anthracycline-containing chemotherapy

    by E. G. Medvedeva, E. N. Yushchuk, S. V. Ivanova, D. A. Filonenko, L. G. Zhukova, O. S. Trofimenko

    Aim. To identify and analyze changes of arterial stiffness (AS) parameters in breast cancer patients undergoing combination anthracycline-containing chemotherapy (ACCT).Material and methods. Fifty women with verified breast cancer aged 46,7±7 years with indications for combined ACCT were assessed for AS (carotid-femoral pulse wave velocity (cfPWV) (m/s); cardio-ankle vascular index (CAVI); cardio-ankle pulse wave velocity (caPWV) (m/s); β-stiffness index, novel Russian Stelari and haStart indices) at 4 visits as follows: before ACCT, after 8-12, 20-24 and 48 weeks from the ACCT start.Results. A reliable decrease in cfPWV was revealed at visit 2 (7,48±1,51, pConclusion. In patients with breast cancer who underwent combined ACCT, an increase in cfPWV by 0,95 m/s per year was revealed, which indicates accelerated vascular wall aging and a possible increase in cardiovascular risk in this category of patients.

  • Open Access

    Particularities of arterial stiffness dynamics on the background of breast cancer chemotherapy

    by Elena N. Yushchuk, Elizaveta G. Medvedeva, Daria A. Filonenko, Svetlana V. Ivanova, Liudmila G. Zhukova, Daria A. Sapunova

    Background. Modern breast cancer chemotherapy regimens (BC) consider individual patient parameters and ranges of cardiotoxic doses. However, clinicians often record clinical and laboratory-instrumental signs of cardio- and vasculotoxicity in patients, which emphasizes the high importance of searching for markers of early toxic response. Aim. To study the characteristics of the response of arterial stiffness on the background of anthracycline-containing chemotherapy to determine potential markers of vasculotoxicity in BC patients. Materials and methods. 20 women with a BC were included. The patients received 4 cycles of chemotherapy in the doxorubicin + cyclophosphane (AC) regimen with an interval of 23 weeks, then they were injected with paclitaxel weekly for 12 injections, or docetaxel once every 3 weeks. All patients underwent TTE, arterial stiffness determination by the "gold standard" method and using volumetric sphygmography before the start of treatment, after the completion of the anthracycline component and after the end of taxanes. Results. The average age of the patients was 45.55.31 years. After completing the course of anthracyclines, there was a significant increase in heart rate (from 65.69.3 to 73.310.1 beats/min.), a decrease in SBP (from 122.69.9 to 116.512.3 mmHg) and DBP (from 78.98.5 to 76.28.6 mmHg), a decrease in carotid femoral pulse wave velocity (cfPWV) (from 9.321.41 to 7.851.57 m/s), CAVI index on the left (from 6.780.81 to 6.50.88), the velocity of the cardio-ankle pulse wave on the right and left (from 6.70.6 to 6.50.7 m/s; from 7.00.6 to 6.30.8 m/sc, respectively). After the completion of the taxane, there was a tendency to increase these indicators, however, they remained significantly lower compared to the values before the start of treatment. Conclusion. A comparative analysis of arterial stiffness indicators at different stages of chemotherapy showed a more pronounced reaction of cfPWV, CAVI, cardio-ankle pulse wave to the administration of anthracyclines, which presumably may be associated with concomitant hemodynamic restructuring.


  • Open Access

    Subclinical markers of liver damage in patients with arterial hypertension and obesity

    by I A Sadulaeva, E N Yushchuk, L F Khalikova, O V Krikunova, O S Trofimenko, E G Medvedeva

    Aim. To investigate the possibility of preclinical detection of liver damage in patients with hypertension and obesity. Materials and methods. The study included 168 patients with hypertension aged 30 to 60 years. All patients underwent general clinical and laboratory-instrumental examination, including ultrasound of the abdominal organs with Doppler assessment of blood flow and determination of markers such as ALT, AST, TG, lipid profile indicators at inclusion, after a month, three months and nine months. Results. Depending on the presence of obesity, all patients with hypertension were divided into two groups. Obese patients had a statistically significant increase in office blood pressure, FSI, the ratio of TG and LDL-C to HDL-C, a more significant higher average levels of glucose, TG and ALT levels, as well as impaired hepatic blood flow according to ultrasound. Conclusion. Indicators of FSI, ALT/AST ratio, ratio of TG and LDL-С to HDL-C as well as assessment of hepatic blood flow indicators can be used for early diagnosis of nonalcoholic fatty liver disease, as they predict liver steatosis.